Multiple silver linings in spite of a soft Q2 24
15/05/24 -"Coloplast reported softer than expected Q2 24 figures. However, with healthy organic growth, the miss reflected FX headwinds, and, hence, was not that worrisome. Importantly, growth was strong across ..."
Pages
75
Language
English
Published on
15/05/24
You may also be interested by these reports :
11/09/26
MedTech sector momentum has finally turned constructive in recent weeks, a welcome change after a multi-year stretch of post-covid destocking, supply ...
08/09/26
Medtech soared after Covid, then dropped out of sight until May 2026. Are its five lean years finally over? MedTech may have found a bottom Covid-era ...
07/09/26
We have revised our estimates upwards and removed the 20% discount previously applied to the peer-based valuation. This optimism is supported by ...
04/09/26
Bastide ended FY25/26 above its revenue target, with Q4 organic growth recovering as the VPH headwind faded, confirming the one-off nature of the ...